Histopathology (03/03/24) Ly, Amy; Garcia, Victor; Blenman, Kim RM; et al.

In an effort to boost pathologists' skills in scoring breast cancer stromal tumor-infiltrating lymphocytes (TILs), experts from the Food and Drug Administration (FDA) teamed up with academic pathologists to develop a continuing medical education (CME) course on the topic. Research shows the prognostic and predictive value of stromal TIL density in breast cancer. However, there is a risk of significant interobserver variability in visual TIL assessment by pathologists. In this report, researchers describe the CME course and an accompanying user guide. The course, which is freely available, features an interactive format and expert commentary. Additionally, the authors note, they "suggest subsequent steps to translate knowledge into clinical practice with proficiency testing."

Read More